5-MTHF enhances the portal pressure reduction achieved with propranolol in patients with cirrhosis: A randomized placebo-controlled trial.
- 2023-10
- RCT
- Journal of hepatology 79(4)
- Ranka Vukotic
- Roberto Di Donato
- Greta Roncarati
- Patrizia Simoni
- Matteo Renzulli
- Stefano Gitto
- Filippo Schepis
- Erica Villa
- Annalisa Berzigotti
- Jaume Bosch
- Pietro Andreone
- PubMed: 37482222
- DOI: 10.1016/j.jhep.2023.06.017
- High evidence
- Clinical
HVPG decreased in both groups, but the magnitude of the change was significantly greater in the group treated with 5-MTHF+propranolol compared to placebo+propranolol (percentage decrease, 20 [29-9] vs. 12.5 [22-0], p=0.028)
- Effect
- Beneficial
- Effect size
- Moderate
- Significant
- Yes